Hims & Hers Health, Inc. HIMS

Hims & Hers Health, Inc. es una plataforma centrada en el consumidor que se enfoca en brindar experiencias personalizadas de salud y bienestar a los consumidores. La plataforma digital de la empresa permite acceder a tratamientos para una variedad de condiciones, incluyendo aquellas relacionadas con la salud sexual, la pérdida de cabello, dermatología, salud mental y atención primaria. Conecta a los pacientes con profesionales de la salud con licencia que pueden recetar medicamentos cuando sea apropiado. Las recetas se cumplen en línea a través de farmacias con licencia en base a suscripción. A través de las aplicaciones móviles de Hims & Hers, los consumidores pueden acceder a una variedad de programas educativos, contenido de bienestar, apoyo comunitario y otros servicios que promueven la salud y el bienestar de por vida. Los productos de la empresa incluyen champú, acondicionador, gomitas de biotina, crema anti-envejecimiento, suero de vitamina C, crema para el acné e hidratante. Sus productos se venden en decenas de miles de ubicaciones minoristas en los Estados Unidos.

• GlobeNewswire Inc. 5 oct

  Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  A class action lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud. The complaint claims the company made false statements about consumer health data privacy, charged patients for prescriptions before medical consultations, and failed to disclose regulatory risks and potential penalties. Investors who purchased Hims securities between August 4, 2025 and July 29, 2026 may be eligible to join the case.

  

• GlobeNewswire Inc. 5 oct

  ROSEN, SKILLED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMS

  Rosen Law Firm is soliciting investors who purchased securities of Hims & Hers Health, Inc. between August 4, 2025 and July 29, 2026 to join a class action lawsuit. The lawsuit alleges that Hims made materially false statements regarding data privacy practices, prescription charging procedures, and regulatory compliance, which subjected the company to potential fees and penalties.

  

• Zacks Investment Research 5 oct

  Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It

  Hims & Hers Health (HIMS) has been trending on Zacks.com with shares up 4.7% over the past month. The company shows strong revenue growth of 49.2% year-over-year for the current quarter and 37% for the fiscal year. However, earnings estimates have been revised downward by 55% over the last 30 days, and the stock carries a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market. The stock is trading at a premium valuation relative to peers.

  

• GlobeNewswire Inc. 2 oct

  ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMS

  A securities class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making materially false and misleading statements regarding consumer data sharing with third-party advertising platforms, charging for prescriptions before medical consultations, and failing to disclose regulatory scrutiny and potential penalties. The lead plaintiff deadline is November 2, 2026.

  

• GlobeNewswire Inc. 2 oct

  Kaplan Fox Notifies Investors of Hims & Hers Health, Inc. (NYSE: HIMS) of a Securities Fraud Class Action Deadline on November 2, 2026

  Kaplan Fox has filed a securities class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased securities between August 4, 2025 and July 29, 2026. The FTC sued the company for allegedly failing to disclose immediate prescription charges, making subscription cancellations difficult, and sharing consumers' health information with third-party advertising platforms like Meta and Snap. The stock fell 14.73% to $25.00 per share following the FTC action. The lead plaintiff deadline is November 2, 2026.